leisure time -WSS

leisure time

author：entertainment 2025-09-30 09:30:10 - browse：21

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Woodcock on FDA’s accelerated approval and her next chapter

WSS

Winning ticket for $1 billion Powerball jackpot sold in California

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Quicker fix for pulse oximeters urged during FDA public meeting

ARCH Venture Partners is raising $3 billion for a life sciences fund

Driven by the pandemic, applicants flood public health schools

Tesla recalling nearly 16,000 of its 2021

Wikipedia

leisure time

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

ARCH Venture Partners is raising $3 billion for a life sciences fund

Tori Bowie and the unacceptable rates of Black maternal death

Awakening the world to the whoosh: A patient's crusade

Cancer drug shortages should be causing more outrage

7 more heat

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Malaria cases in Florida and Texas: Here’s what you need to know

Divers poised to search for children washed away in Pennsylvania flash flood

leisure time

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

I learned firsthand about improving diversity in clinical trials

Indian pharmaceutical industry in denial over drug

The lessons of Aduhelm, an Alzheimer's drug that was not to be

The real point of Kenneth Smith’s execution by nitrogen gas

I learned firsthand about improving diversity in clinical trials

hotspot

focus

explore

Wikipedia